Delivery Order SPE2DB24D1104-SPE2DB25FYDY4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Everolimus 0.75 mg tablets (60-count) with a ceiling value of $6,624.37. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by August 11, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under a larger vehicle and carries no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Everolimus 5 mg tablets in quantities of 30 units, with a ceiling value of $19,375.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on July 23, 2025, with performance being executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Everolimus 1 mg tablets (60-count) with a ceiling value of $16,540.67. This firm fixed-price delivery order is not set-aside and represents a competitive award to the prime contractor. The contract is set to be completed by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Everolimus 5 mg tablets (30-count packages) with a ceiling value of $44,765.09. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 13, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,167.64 firm fixed-price contract is for the delivery of Everolimus 5 mg tablets. The contract has an ultimate completion date of May 1, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,856.17 to AmerisourceBergen Drug Corp for the supply of Everolimus 1 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order carries an ultimate completion date of August 12, 2025, with performance occurring at...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Everolimus 7.5 mg tablets. The contract has a ceiling value of $10,882.45 and an ultimate completion date of June 18, 2025. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Everolimus 3 mg tablets for suspension, with a ceiling value of $37,576.08 and a performance period through December 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at...
- This is a federal delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $5,153.99 fixed-price contract is for the delivery of Everolimus 0.75 mg tablets, a medication, with a period of performance through July 16, 2025. The contract is not set aside and is funded by the Defense agency. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $11,525.17 firm fixed-price delivery order is for the supply of 0.75 mg Everolimus tablets. The contract has a completion date of June 5, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as the primary vehicle for providing a...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYDY4Delivery Order
The Defense Logistics Agency awarded a $3,978.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs and federal medical procurement needs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its critical role as a major pharmaceutical distributor and healthcare solutions provider supporting defense and civilian federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 7/30/25 |